Pharmacokinetics of lansoprazole injection in peptic ulcer and healthy volunteers

The pharmacokinetics of lansoprazole after a single intravenous dose of 30 mg was determined in 10 healthy volunteers and 10 peptic ulcers patients. In this work, a liquid-liquid extraction and enrichment method with RP-HPLC determination route was taken with high sensitivity and low limit detection of 5 ng/mL. The concentration-time curves in the two groups were best fitted to a two-compartment model, but their main kinetic parameters were remarkably different between healthy and ulcers volunteers. The mean maximum plasma concentration (Cmax ) and area under the curve (AUC0t ) were increased from 975.8 ng/mL to 1298.7 ng/mL and from 1439 ng·h/mL to 2301 ng·h/mL, respectively, and peak time (tmax ) decreased from 0.36 h to 0.26 h. Meanwhile, the half life (t1/2 ) prolonged from 2.25 h to 2.91 h and the clearance (CL) reduced from 20.04 L/h to 13.96 L/h. That variability of lansoprazole pharmakinetic parameter indicates that ulcers have significant effect on its metabolic process.Colegio de Farmacéuticos de la Provincia de Buenos Aire

miR-216b Post-Transcriptionally Downregulates Oncogene KRAS and Inhibits Cell Proliferation and Invasion in Clear Cell Renal Cell Carcinoma

Background/Aims: Increasing evidence has shown that miR-216b plays an important role in human cancer progression. However, little is known about the function of miR-216b in renal cell carcinoma. Methods: The expression levels of miR-216b in renal cell carcinoma tissues and cell lines were examined by qRT-PCR. The biological role of miR-216b in renal cell carcinoma proliferation and/or metastasis was examined in vitro and in vivo. The target of miR-216b was identified by a dual-luciferase reporter assay. The expression level of KRAS protein was measured by western blotting. Results: The expression of miR-216b was downregulated in clear cell renal cell carcinoma (ccRCC) cell lines and specimens compared to the adjacent normal tissues. Furthermore, miR-216b can bind to the 3’untranslated region (UTR) of KRAS and inhibit the expression of KRAS through translational repression. The in vitro study revealed that miR-216b attenuated ccRCC cell proliferation and invasion. Furthermore, in vivo study also showed that miR-216b suppressed tumor growth. MiR-216b exerted its tumor suppressor function through inhibiting the KRAS-related MAPK/ERK and PI3K/AKT pathways. Conclusion: Our findings provide, for the first time, significant clues regarding the role of miR-216b as a tumor suppressor by targeting KRAS in ccRCC

Nutritional and medicinal characteristics of Chinese giant salamander (Andrias davidianus) for applications in healthcare industry by artificial cultivation: A review

Andrias davidianus, i. e. Chinese giant salamander (CGS), is one of the largest and oldest amphibians existing in the world and is also one of the valuable biological resources of China. Wild CGS has been threatened with extinction in the past decades due to over capturing, deterioration of natural environment, the slow breeding and growth of the wild species in nature. However, in the past twenty years, with the breakthrough and progress of artificial breeding technology by artificial insemination, the number of artificially cultivated CGS has increased rapidly. Artificially cultivated CGS can either be released to the CGS living environment to increase the population in nature or legally applied in food and medicinal industry as a feedstock due to the unique nutritional and medicinal values of CGS as recorded historically. In this review, the nutritional components, bioactive components and medicinal activities of the artificially cultivated CGS will be summarized. The mucus, skin, meat and bone of CGS contain many different bioactive substances thereby having various medicinal activities including anti-aging, anti-fatigue, anti-tumor, therapy of burn and anti-infection and other physiological functions. This paper will further discuss the potential applications of the artificially cultivated CGS in healthcare industry and prospects of future technological development

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

BACKGROUN

Alirocumab and cardiovascular outcomes after acute coronary syndrome

BACKGROUN